Search results for "α-Synuclein"

showing 10 items of 10 documents

Focus on the Small GTPase Rab1: A Key Player in the Pathogenesis of Parkinson’s Disease

2021

Parkinson’s disease (PD) is the second most frequent neurodegenerative disease. It is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of large aggregates in the survival neurons called Lewy bodies, which mainly contain α-synuclein (α-syn). The cause of cell death is not known but could be due to mitochondrial dysfunction, protein homeostasis failure, and alterations in the secretory/endolysosomal/autophagic pathways. Survival nigral neurons overexpress the small GTPase Rab1. This protein is considered a housekeeping Rab that is necessary to support the secretory pathway, the maintenance of the Golgi complex structure, and the regulation of macroau…

autophagyParkinson's diseaseQH301-705.5Substantia nigraReviewBiologyCatalysisInorganic Chemistryα-synucleinmedicineAnimalsHumansSmall GTPaseBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopySecretory pathwayRab1GTPasesOrganic ChemistryNeurodegenerationDopaminergicRAB1Parkinson DiseaseLRRK2General Medicinemedicine.diseaseLRRK2Computer Science Applicationssecretory pathwayrab1 GTP-Binding ProteinsChemistrynervous systemParkinson’s diseaseNeuroscienceGolgi fragmentationInternational Journal of Molecular Sciences
researchProduct

Cholesterol facilitates interactions between α‐synuclein oligomers and charge‐neutral membranes

2015

AbstractOligomeric species formed during α-synuclein fibrillation are suggested to be membrane-disrupting agents, and have been associated with cytotoxicity in Parkinson’s disease. The majority of studies, however, have revealed that the effect of α-synuclein oligomers is only noticeable on systems composed of anionic lipids, while the more physiologically relevant zwitterionic lipids remain intact. We present experimental evidence for significant morphological changes in zwitterionic membranes containing cholesterol, induced by α-synuclein oligomers. Depending on the lipid composition, model membranes are either unperturbed, disrupt, or undergo dramatic morphological changes and segregate …

AmyloidParkinson's diseaseFluorescent DyeBiophysicsPlasma protein bindingBiochemistryOligomerProtein Structure SecondaryMultiphoton microscopyMembrane phase separationCell membranechemistry.chemical_compoundGeneticStructural Biology2-NaphthylamineLaurdan fluorescenceGeneticsFluorescence microscopemedicineMolecular BiologyFluorescent DyesLaurateα-SynucleinMembranesChemistryMedicine (all)2-NaphthylamineCell MembraneMembraneCell BiologySettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)CholesterolMembranemedicine.anatomical_structureBiophysicBiochemistryStructural biologyOligomeralpha-SynucleinParkinson’s diseaseProtein MultimerizationLaurdanLauratesProtein BindingFEBS Letters
researchProduct

Fabry Disease With Concomitant Lewy Body Disease

2019

AbstractAlthough Gaucher disease can be accompanied by Lewy pathology (LP) and extrapyramidal symptoms, it is unknown if LP exists in Fabry disease (FD), another progressive multisystem lysosomal storage disorder. We aimed to elucidate the distribution patterns of FD-related inclusions and LP in the brain of a 58-year-old cognitively unimpaired male FD patient suffering from predominant hypokinesia. Immunohistochemistry (CD77, α-synuclein, collagen IV) and neuropathological staging were performed on 100-µm sections. Tissue from the enteric or peripheral nervous system was unavailable. As controls, a second cognitively unimpaired 50-year-old male FD patient without LP or motor symptoms and 3…

complications [Lewy Body Disease]MalePathologyAutopsyDisease0302 clinical medicineHypokinesiapathology [Brain]Lysosomal storage diseasespathology [Neurons]metabolism [alpha-Synuclein]metabolism [Fabry Disease]pathology [Astrocytes]Neuronsα-Synuclein0303 health sciencesParkinsonismTrihexosylceramidesBrainGeneral MedicineMiddle AgedParkinson diseasecomplications [Fabry Disease]Neurologymetabolism [Neurons]alpha-Synucleinmedicine.symptomLewy Body Diseasemedicine.medical_specialtymetabolism [Lewy Body Disease]Context (language use)Substantia nigrametabolism [Trihexosylceramides]Pathology and Forensic Medicineblood supply [Brain]03 medical and health sciencesCellular and Molecular Neuroscienceα-Galactosidase AmedicineHumansddc:610030304 developmental biologypathology [Lewy Bodies]Fabry diseasebusiness.industryPars compactapathology [Lewy Body Disease]Lewy bodies/neuritesOriginal Articlesmetabolism [Lewy Bodies]medicine.diseaseFabry diseasemetabolism [Brain]AstrocytesLewy BodiesNeurology (clinical)CD77pathology [Fabry Disease]business030217 neurology & neurosurgeryJournal of Neuropathology and Experimental Neurology
researchProduct

Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders

2022

Recently, the synaptic proteins neurogranin (Ng) and α-synuclein (α-Syn) have attracted scientific interest as potential biomarkers for synaptic dysfunction in neurodegenerative diseases. In this study, we measured the CSF Ng and α-Syn concentrations in patients affected by AD (n = 69), non-AD neurodegenerative disorders (n-AD = 50) and non-degenerative disorders (n-ND, n = 98). The concentrations of CSF Ng and α-Syn were significantly higher in AD than in n-AD and n-ND. Moreover, the Aβ42/Ng and Aβ42/α-Syn ratios showed statistically significant differences between groups and discriminated AD patients from n-AD patients, better than Ng or α-Syn…

Alzheimer’s disease; biomarkers; neurogranin; α-synucleinAmyloid beta-PeptidesneurograninOrganic ChemistrybiomarkersNeurodegenerative Diseasestau ProteinsGeneral MedicineCatalysisSettore MED/01 - Statistica MedicaComputer Science ApplicationsInorganic Chemistryα-synucleinAlzheimer DiseaseFluorodeoxyglucose F18alpha-SynucleinHumansCognitive DysfunctionSettore MED/26 - NeurologiaPhysical and Theoretical ChemistryAlzheimer’s diseaseMolecular BiologySpectroscopyInternational Journal of Molecular Sciences; Volume 23; Issue 18; Pages: 10831
researchProduct

Selective α-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for parkinson’s disease

2018

Progressive neuronal death in brainstem nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson’s disease (PD). Reduction of α-synuclein levels is therefore a potential therapy for PD. However, because α-synuclein is essential for neuronal development and function, α-synuclein elimination would dramatically impact brain function. We previously developed conjugated small interfering RNA (siRNA) sequences that selectively target serotonin (5-HT) or norepinephrine (NE) neurons after intranasal administration. Here, we used this strategy to conjugate inhibitory oligonucleotides, siRNA and antisense oligonucleotide (ASO), with the triple monoamine reuptake …

0301 basic medicineanimal diseasesDopamineOligonucleotidesGene ExpressionPharmacologySynaptic TransmissionPrefrontal cortexMiceDA neurotransmission0302 clinical medicineDrug DiscoveryMonoaminergicNeural PathwaysRNA Small InterferingCells Cultured5-HT neurotransmissionChemistryGene Transfer TechniquesParkinson DiseaseVentral tegmental areaSubstantia Nigramedicine.anatomical_structureCaudate putamenGene Knockdown Techniquesalpha-SynucleinMolecular MedicineRNA InterferenceOriginal ArticleMonoamine reuptake inhibitormedicine.drugSignal TransductionSerotoninSubstantia nigraASO03 medical and health sciencesProsencephalonα-synucleinDopamineIntranasal administrationGeneticsmedicineAnimalsHumansMolecular BiologyAdministration IntranasalPharmacologyPars compactaDopaminergic NeuronsGenetic TherapyCorpus Striatumnervous system diseases030104 developmental biologyMonoamine neurotransmitterGene Expression Regulationnervous systemsiRNAParkinson’s diseaseLocus coeruleus030217 neurology & neurosurgery
researchProduct

Formation of covalent di-tyrosine dimers in recombinant α-synuclein

2015

Parkinson's disease is associated with fibril deposition in the diseased brain. Misfolding events of the intrinsically disordered synaptic protein α-synuclein are suggested to lead to the formation of transient oligomeric and cytotoxic species. The etiology of Parkinson's disease is further associated with mitochondrial dysfunction and formation of reactive oxygen species. Oxidative stress causes chemical modification of native α-synuclein, plausibly further influencing misfolding events. Here, we present evidence for the spontaneous formation of covalent di-tyrosine α-synuclein dimers in standard recombinant protein preparations, induced without extrinsic oxidative or nitrative agents. The…

chemistry.chemical_classificationReactive oxygen speciesParkinson's diseasealphasynucleinamyloids di-tyrosine dimers EOM Parkinson’s disease SAXSSAXSOxidative phosphorylationFibrilmedicine.disease_causeIndustrial and Manufacturing Engineeringchemistry.chemical_compoundα-synucleinMonomerchemistryBiochemistryCovalent bondmedicinedi-tyrosine dimersamyloidsTyrosineProtein secondary structureEOMOxidative stressResearch PaperIntrinsically Disordered Proteins
researchProduct

6-Hydroxydopamine lesioning differentially affects α-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats

2002

The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion and/or repeated administration of levodopa (L-DOPA) to normal and 6-OHDA-lesioned rats on alpha-synuclein mRNA expression was investigated by in situ hybridization histochemistry. A 6-OHDA lesion of the nigro-striatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA expression, markedly decreased alpha-synuclein mRNA in the lesioned substantia nigra (SN). In contrast, the levels of alpha-synuclein mRNA in the denervated striatum and nucleus accumbens were not altered. Chronic administration of L-DOPA to normal or 6-OHDA-lesioned rats had no effect on alpha-synuclein mRNA expression in the SN, striatum or nu…

Malemedicine.medical_specialtyTyrosine 3-MonooxygenaseDopamineanimal diseasesDopamine AgentsSynucleinsNerve Tissue ProteinsSubstantia nigraStriatumNucleus accumbensBiologyDrug Administration ScheduleNucleus Accumbenschemistry.chemical_compoundDopamineInternal medicineBasal gangliamedicineAnimalsTyrosine hydroxylase mRNARNA MessengerRats WistarOxidopamineNeuronsHydroxydopamineTyrosine hydroxylaseGeneral NeuroscienceParkinson Diseaseα-Synuclein mRNARatsnervous system diseasesNeostriatumSubstantia NigraEndocrinologynervous systemchemistrySympatholyticsalpha-SynucleinSettore BIO/14 - Farmacologia6-HydroxydopamineOxidopaminemedicine.drugNeuroscience Letters
researchProduct

Microglia and α-synuclein implication in Parkinson's disease

2011

Age-related neurodegenerative disorders like Parkinson’s disease take an enormous toll on individuals and on society. Despite extensive efforts, Parkinson’s disease remains incurable and only very limited treatments exist. Indeed, Parkinson’s pathogenesis is still not clear and research on its molecular mechanisms is ongoing. In this study, we focused our interest on two abnormal events occurring in Parkinson’s patients, namely α-synuclein aggregation and microglial activation. We first investigated α-synuclein and its abnormal polymerisation. For this purpose, we developed novel methods, which allowed the in vitro production of different types of α-synuclein oligomers. Using highly sensiti…

[SDV.SA]Life Sciences [q-bio]/Agricultural sciencesΑ-synucléineAgingMaladie de ParkinsonDopamineCultures primairesBrain immunityNeuronesVieillissementImmunité du cerveauPotassium channelsNeuroinflammationToxicitéC8-B4 cell line[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMéthode d’isolation in vitroElectrophysiologieCanaux potassiquesNeurodegeneration[ SDV.SA ] Life Sciences [q-bio]/Agricultural sciencesIn vitro isolation methodPrimary cultureKv1.3 - Kir2.1Neurons[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyToxicityMaladies neurodégénérativesΑ-synucleinNitric oxideNeurodégénérationOligomèresElectrophysiologyMicrogliesBrain macrophagesOligomersOxyde nitriqueNeurodegenerative disordersParkinson’s diseaseCytokinesLignée cellulaire C8-B4MicrogliaPatch-clamp[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.

2010

Although generally considered a prototypical movement disorder, Parkinson's disease is commonly associated with a broad-spectrum of non-motor symptoms, including autonomic dysfunctions caused by significant alterations in catecholaminergic neurons of the peripheral sympathetic nervous system. Here we present evidence that alpha-synuclein is highly expressed by sympathetic ganglion neurons throughout embryonic and postnatal life and that it is found in tyrosine hydroxylase-positive sympathetic fibers innervating the heart of adult mice. However, mice deficient in alpha-synuclein do not exhibit any apparent alterations in sympathetic development. Sympathetic neurons isolated from mouse embryo…

Sympathetic nervous system1-Methyl-4-phenylpyridiniumα-Synuclein knockoutTyrosine 3-MonooxygenaseNeurotoxinsNeurotrophic factorSubstantia nigraBiologylcsh:RC321-571chemistry.chemical_compoundMiceCatecholaminesSympathetic Fibers PostganglionicParkinsonian DisordersNeurotrophic factorsmedicineNeurotoxinAutonomic gangliaAnimalslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryCells CulturedNeuronsGanglia SympatheticCell DeathMPTPSympathetic ganglionMice Mutant Strainsnervous system diseasesMPP+medicine.anatomical_structureNeurologychemistrynervous system1-Methyl-4-phenyl-1236-tetrahydropyridinePeripheral nervous systemSympathetic nervous systemNerve Degenerationalpha-SynucleinCatecholaminergic cell groupsPeripheral nervous systemNeuroscienceNeurobiology of disease
researchProduct

Neurogranin as a Novel Biomarker in Alzheimer's Disease

2020

Abstract Background In this study, we investigated the possible role of 2 novel biomarkers of synaptic damage, namely, neurogranin and α-synuclein, in Alzheimer disease (AD). Methods The study was performed in a cohort consisting of patients with AD and those without AD, including individuals with other neurological diseases. Cerebrospinal fluid (CSF) neurogranin and α-synuclein levels were measured by sensitive enzyme-linked immunosorbent assays (ELISAs). Results We found significantly increased levels of CSF neurogranin and α-synuclein in patients with AD than those without AD. Neurogranin was correlated with total tau (tTau) and phosphorylated tau (pTau), as well as with cognitive declin…

MaleOncologymedicine.medical_specialtyClinical BiochemistryDiseaseSensitivity and SpecificityCerebrospinal fluidAlzheimer DiseaseInternal medicineHumansMedicineNeurograninCognitive declineAgedRetrospective StudiesReceiver operating characteristicbusiness.industryBiochemistry (medical)Area under the curveMiddle Agedmedicine.diseaseCSF biomarker neurogranin synapsis synaptic loss α-synucleinalpha-SynucleinBiomarker (medicine)FemaleNeurograninAlzheimer's diseasebusinessBiomarkers
researchProduct